BridgeMD
Long-term outcomes and safety of repeated rituximab treatment in psychotic disorders – RITS-LONG
EU CTIS ID: 2026-525324-26-00
What this study is testing
To investigate the long-term outcomes and safety from repeated adjuvant treatment with the immunomodulatory drug rituximab in patients with schizophrenia or schizoaffective disorder.
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Have participated in the RCT-Rits trial.
- Signed informed consent.
- Duration of illness exceeding 2 years.
- Meets DSM-5 diagnostic criteria for schizophrenia or schizoaffective disorder at Baseline in RCT-Rits.
- Women (WOCBP) must be willing to use contraceptives or abstain for the duration of the study until one year after last rituximab treatment.
- Subjects should be assessed by the investigator to be clear and oriented when giving informed consent.
You likely can't join if
- Pregnancy or breastfeeding.
- Malignancy, currently or within three years prior to inclusion.
- Hypogammaglobulinemia or neutropenia.
- Any other physical condition that, in the judgement of the investigator, would make the subject unsuitable for participation in the trial.
- Weight below 40 kg.
- Clinically relevant ongoing infection.
See the full eligibility criteria
- Have participated in the RCT-Rits trial.
- Signed informed consent.
- Duration of illness exceeding 2 years.
- Meets DSM-5 diagnostic criteria for schizophrenia or schizoaffective disorder at Baseline in RCT-Rits.
- Women (WOCBP) must be willing to use contraceptives or abstain for the duration of the study until one year after last rituximab treatment.
- Subjects should be assessed by the investigator to be clear and oriented when giving informed consent.
- Pregnancy or breastfeeding.
- Malignancy, currently or within three years prior to inclusion.
- Hypogammaglobulinemia or neutropenia.
- Any other physical condition that, in the judgement of the investigator, would make the subject unsuitable for participation in the trial.
- Weight below 40 kg.
- Clinically relevant ongoing infection.
- Chronic infections.
- Positive screening test for hepatitis B, C, HIV, or tuberculosis at Baseline in RCT-Rits.
- Severe heart disease.
- Unable to make an informed decision to consent.
- Treatments with monoclonal antibodies (other than rituximab), other immunomodulation treatments, or cytostatics within one year prior to inclusion.
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.